期刊文献+

华法林对老年心房颤动患者内皮功能及凝血系统的作用 被引量:6

The effects of warfarin on endothelial function and coagulation system in elderly patients with atrial fibrillation
原文传递
导出
摘要 目的观察华法林对老年心房颤动(房颤)患者内皮功能和凝血系统的影响。方法对2007年3月至2010年12月住院的126例老年房颤患者进行分组观察,将患者分为华法林组(57例,予华法林抗凝治疗)和阿司匹林组(69例,予阿司匹林抗血小板凝集治疗),并和42例无房颤的同期患者(对照组)进行对照;3组性别、年龄、BMI、血压、基础疾病、常规治疗药物等基线资料均衡(P均>0.05)。观察治疗前后患者内皮功能及凝血系统的变化。结果华法林组及阿司匹林组患者血浆血管性假血友病因子(vWF)、纤维蛋白原(Fg)、D-二聚体(D-Dimer)浓度均较对照组明显增高(P均<0.01)。与阿司匹林组相比,华法林组抗凝治疗后,vWF、Fg、D-Dimer浓度都有明显下降(P均<0.05);体循环栓塞事件发生率有所降低,但差异无统计学意义(5.26%vs13.0%,P>0.05)。结论华法林可以显著降低房颤患者的血浆vWF、Fg、D-Dimer浓度,改善其内皮细胞功能和凝血功能,从而减少血栓栓塞的风险。 Objective To observe the effects of warfarin on endothelial function and coagulation system in elderly patients with atrial fibrillation (AF). Methods A total of 126 elderly patients with AF hospitalized between March 2007 and December 2010 were divided into two groups: warfarin group (n =57 ,using warfarin) and aspirin group ( n = 69, using aspirin), and 42 non-AF patients admitted at corresponding period were selected as control group. The basic data including sex, age, body mass index, blood pressure, underlying diseases, routine therapy were matched( all P 〉 O. 05 ). The changes of endothelial function [ von willebrand factor (vWF) as an index] and coagulation system [ fibrinogen (Fg) and D-Dimer as indexes ] before and after warfarin or aspirin therapy were observed and compared with control group. Results Compared with control group, concentrations of plasma vWF, Fg and D-Dimer before therapy in warfarin and aspirin groups increased significantly ( all P 〈 0. O1 ). Compared with aspirin group after aspirin therapy, the concentrations of plasma vWF, Fg and D-Dimer after warfarin therapy significantly declined ( all P 〈 0.05 ), and the incidence of thromboembolism events of systemic circulation decreased,but there was no singnifieant difference ( 5.26% vs 13.0%, P 〉 0.05 ). Conclusion Warfarin could significantly reduce the concentrations of vWF, Fg and D-Dimer in elderly AF patients, and improve endothelial function and coagulation function thereby lower the risk of thromboembolism.
出处 《中国临床研究》 CAS 2013年第2期113-115,共3页 Chinese Journal of Clinical Research
关键词 心房颤动 血管性假血友病因子 纤维蛋白原 D-二聚体 血栓栓塞 Atrial Fibrillation von Willebrand factor Fibrinogen D-Dimer Thromboembolism
  • 相关文献

参考文献9

  • 1马长生,周玉杰,马煜,郑知刚,颜红兵,王勇,李霄,柯元南,汤旦林.北京地区非瓣膜病心房颤动患者缺血性脑卒中发生率及影响因素的随访研究[J].中华心血管病杂志,2002,30(3):165-167. 被引量:148
  • 2Waldo AL. Anticoagulation:stroke prevention in patients with atrial fibrillation[J].Cardiology Clinics,2009,(01):125-135.
  • 3Anon. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.Analysis of pooled data from five randomized controlled trials[J].Archives of Internal Medicine,1994,(13):1449-1457.
  • 4van Walraven C,Hart RG,Singer DE. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation:an individual patient metaanalysis[J].Journal of the American Medical Association,2002,(19):2441-2448.
  • 5Feng D,D'Agostino RB,Silbershatz H. Hemostatic state and atrial fibrillation(the Framingham of Spring Study)[J].American Journal of Cardiology,2001,(02):168-171.
  • 6Brown N J,Kumal S,Painter CA. ACE inhibition versus angiotensin type 1 receptor antagonism:differential effects on PAL-1 over time[J].Hypertension,2002,(06):859-865.doi:10.1161/01.HYP.0000040264.15961.48.
  • 7Conway DS,Pearce LA,Chin BS. Prognostic value of plasma yon Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation[J].Circulation,2003,(25):3141-3145.doi:10.1161/01.CIR.0000077912.12202.FC.
  • 8Mügge A. Anticoagulation in patients with atrial fibrillation[J].Herz,1996,(01):28-36.
  • 9Mant J,Hobbs FD,Fletcher K. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Birmingham Atrial Fibrillation Treatment of the Aged Study,BAFTA):a randomized controlled trial[J].The Lancet,2007,(9586):493-503.

二级参考文献10

  • 1Saoudi N,Schoels W,EL-Sherif N,eds.Atrial flutter and fibrillation:from basic to clinical applications[]..1998
  • 2Wolf PA,Abbott RD,Kannel WB.Atrial fibrillation as an independent risk factor for stroke: the Framingham study[].Stroke.1991
  • 3Caro JJ,Flegel KM,Orejuela ME,et al.Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice[].Canadian Medical Association Journal.1999
  • 4Flegel KM,Shipley MJ,Rise G.Risk of stroke in non-rheumatic atrial fibrillation[].The Lancet.1987
  • 5Yamaguchi T.Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation[].Stroke.2000
  • 6Hart RG,Sherman DG,Easton JD,et al.Prevention of stroke in patients with nonvalvular atrial fibrillation[].Neurology.1998
  • 7Peterson P,Boysen G,Godtfredsen J,et al.Placebo controlled,randomized trial of warfarin and aspirin for prevention of thromboembolic complications on chronic atrial fibrillation: the Compenhagen AFASAK study[].The Lancet.1989
  • 8Feinberg WM,Blackshear JL,Laupacis A,et al.Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications[].Archives of Internal Medicine.1995
  • 9Ezekowitz MD,Bridgers SL,James KE,et al.Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation:Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators[].The New England Journal of Medicine.1992
  • 10Connolly SJ,Laupacis A,Gent M,et al.Canadian atrial fibrillation anticoagulation (CAFA) study[].Journal of the American College of Cardiology.1991

共引文献147

同被引文献61

  • 1姚光辉,杨荣平.80例老年人心房颤动的临床分析[J].实用心电学杂志,2006,15(2):87-88. 被引量:2
  • 2刘积伦,武胜,高爱红,田燕妮,朱彩霞,李军朋.老年心房颤动患者的华法林抗凝治疗[J].中国煤炭工业医学杂志,2006,9(9):973-974. 被引量:4
  • 3宗立庚,吴素华,姜风琴,吕钰,贺树凤.噻氯吡啶与华法林治疗心腔内附壁血栓的临床对比研究[J].中国煤炭工业医学杂志,2007,10(9):1016-1017. 被引量:2
  • 4李为东,李先进,朱可,付强,宫海滨.75岁以上持续性心房颤动患者华法林抗凝治疗的临床观察[J].血栓与止血学,2007,13(6):270-271. 被引量:3
  • 5Kannel WB, D' Agostino RB, Wilson PW, et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the framingham experience [ J ]. Am Heart J, 1990,120 (3) :672 - 676.
  • 6Johnson CE, Lira WK, Workman BS. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up [ J ]. J Am Geriatr Soc, 2005,53(4) :655 -659.
  • 7,quang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYt~2C9 genntypes on interindividual warfarin maintenance dose: a prospective study in C~inese patients[ J]. Pha~acoget~et Geno~ics,2009,19(3) :226 -234.
  • 8Epstein RS, Moyer TP, Aubert RE, et al. Warfarin gen~typing re- duces hospitalization rates results from the MM-WES ( Medc'o-May~~ Warfarin Effectiveness study ) [ J ]. J Am Coil Cardiol, 2010, 55 (25) :2804 -2812.
  • 9|身}爽.VKORC1与CYP2c9基因多态性对中国人口服华法林起始抗凝效果影响的研究[D].北京:中国协和医科大学,2009.
  • 10Miao L, Yang J, Huang C, et al. Contribution of age, body weight and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin :proposal for a new dosing regimen in Chinese patients[ J ]. Eur J Clin Pharmacol,2007,63 ( 12 ) : 1135 - 1141.

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部